News 
Market Data 
Discover
typing on the computer about my status
Verticalmojo
typing on the computer about my status
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
typing on the computer about my status
L2 LOL BUYING COMING IN!
SEE ACCUMILATION!!!!!
(@)-;--'-shares now available for merger/acquisition/partnership!-'--;-(@)
Anyone who thinks it would be better if the company did not raise the A/S is crazy this doesn't effect the float. Now the company has shares available for merger/acquisition/partnership. If they had not increased the A/S, they would be not be in a position to enter into those partnerships. They also had to protect themselves as they would have been vulnerable to hostile takeover from another company or person buying up a majority of shares.
@)--;--WELCOME TO SOLOS ENDOSCOPY--;-(@
THIS IS A VERY EXCITING TIME AS SNDY IS EMERGING INTO A NEW LEVEL.
SNDY HAS MADE MANY ADVANCEMENTS IN THE PAST 3 YEARS
A COMPANY THAT FOCUSES ON RESEARCH & DESIGN, ITS PRODUCTS ARE STATE OF THE ART AND HAVE SHOWN TO DETECT BREAST CANCER IN THE EARLY STAGE THAT CAN BE UNDETECTABLE WITH STANDARD MAMOGRAPH CHECKUPS.
SNDY IS SAVING LIVES, AND THAT IS A FACT
THE DEMAND FOR EARLY DETECTION IS INCREASING RAPIDLY
SNDY WILL MEET THAT DEMAND
_____________________________________________________________
SNDY A REAL COMPANY
SNDY IS LIKE NO OTHER PINK (DO THE DD)
SNDY AS A COMPANY IS EMERGING INTO A NEW MARKET
SNDY HAS OVER 200 FDA APPROVED MEDICAL DEVICES
SNDY MANAGEMENT AGREED ON A MERGER/ACQUISITION PLAN IN 2007
*****
SNDY HAS COMPLETED AUDIT STAGE 1 FOR ISO 13485 WITH NO DELAY
SNDY HAS A SCHEDUALED AUDIT WITH TÜV ON 8/16/2013
SNDY WILL HAVE THE GREEN LIGHT TO OBTAIN CE MARK
SNDY HIRED EXPERT RECOURCES TO ENSURE SUCCESFUL COMPLETION
EXPERT RECOURCES HAS A PERFECT RECORD IN PASSING AUDITS.
SNDY HIRED EMERGO GROUP AS THEIR EUROPEAN ATHORIZED REPRESENTIVE
*****
SNDY will be FDA + ISO 13485 + CE Mark approved (VERY RARE IN PINKS)
SNDY WILL OPEN DOORS TO A 90+ BILLION DOLLAR MARKET WITH CE MARK
95% of small company's who have FDA and CE mark exit via merger/acquisition
http://dspace.mit.edu/handle/1721.1/65522
*****
insert-text-here
http://www.zapconnect.com/companies/index.cfm/fuseaction/companies_detail/eregnum/1223105.html#!/exjun_
*****
SDNY WILL RECIEVE AND HAVE THESE MARKS SOON AFTER SUCCSEFUL AUDIT COMPLETION.
THESE BILLION DOLLLAR COMPANYS DEPEND ON THE R&D OF SMALLER COMPANIES TO GROW THEIR CATALOGS AND TO DOMINATE THE MARKET BY BUYING THEIR COMPETITORS
*****
insert-text-here
*************LOCATION & HEADQUARTERS**************
SOME GREAT POSTS ON THE SNDY BOARD
[url]Quote:
--------------------------------------------------------------------------------
LOOKS LIKE SNDY JUST STEPPED UP THEIR GAME...
in the hiring of Emergo Group. SNDY is taking this final audit as serious as they can. Not only do they have Expert Resources to over see this audit but have now brought in Emergo.
What is Emergo role? Here we go:
ISO 13485 Audits for Medical Device Companies.
Medical device manufacturers are required to regularly conduct an audit of their ISO 13485 compliant quality management system. Emergo Group conducts these fully independent quality system reviews for companies that are already ISO 13485 certified as well as for firms about to undergo their initial ISO 13485 certification audit by a Notified Body or Registrar.
Not only that but look how well Emergo takes care of their customers once hired:
Emergo Group provides the following ISO 13485 auditor services:
These ISO 13485 audits help determine the actual status of your current quality management system and processes:
•Off-site review of your current QA/RA documentation prior to your on-site ISO 13485 audit by a Notified Body or Registrar
•Systematic and independent process audit to determine conformity or nonconformity of your Quality Management System to ISO 13485:2003 requirements
•Review of your internal documentation to verify that all requirements have been addressed
•Actual verification of ISO 13485 audit requirements through review of objective evidence
•Physical verification of compliance via interviews and fact-based observations to confirm quality system requirements
•Evaluation of current special controls or validated processes; knowledgeable in various processes such as sterilization, clean-rooms, or software systems
Emergo Group also provides on-site ISO 13485 auditor training in order for clients to effectively audit their own quality systems. Our training is classroom-based and teaches your employees how to become ISO 13485 internal auditors to ensure proper functioning of your QMS. Key topics of the training include why ISO audits are required, planning an internal audit, as well as conduct and performance issues related to ISO 13485 internal audits.
CE Certification – CE Mark Certification for Medical DevicesSee all regulatory consulting services and medical device registration services.
In order to commercialize medical and in vitro diagnostic devices in the European Union, manufacturers must obtain CE Marking certification and affix the CE marking as part of their device registration efforts.
CE Marking certification verifies to EU regulators that your device meets all requirements of the Medical Devices Directive (MDD), In Vitro Diagnostic Device Directive (IVDD) or Active Implantable Medical Device Directive (AIMD) as they apply to your product. You must obtain CE Marking certification prior to marketing, distribution and sale of your product in any EU member state.
You are solely responsible as the medical device manufacturer for maintaining compliance with EU directives and securing CE Marking certification for your product, regardless of whether you outsource any or all components of your manufacturing operation.
Qualifying for CE certification and marketing your medical device in the EU requires the following steps:
1.Prepare a CE Marking Technical File or a Design Dossier for a Class III device that includes data proving compliance with the MDD, IVDD or AIMD.
2.Obtain your CE Marking certificate from a Notified Body.
3.Select and appoint a European Authorized Representative to act on your behalf within the EU.
4.Register your medical device with the appropriate Competent Authority, if necessary.
Completion of these requirements allows you to claim CE Marking certification for your device.
Looks like to me SNDY just took care of #3 with todays news.
Emergo Group has a well-established presence in the EU, with offices in the UK, Germany, France and the Netherlands. We have assisted hundreds of medical device manufactures with their CE Marking certification efforts. Services we provide to help you obtain CE certification include product classification; technical file and design dossier preparation; ISO 13485 quality system implementation and auditing; and ISO 14971 risk assessment and management.
Why choose Emergo Group as your ISO 13485 consultant?
With over 20 local offices worldwide, Emergo Group has helped hundreds of medical device and IVD manufacturers implement quality systems that meet the ISO 13485 standard. Our team of experienced ISO 13485 consultants have implemented numerous quality management systems for companies manufacturing a wide range of medical devices.
Our system has been proven to work efficiently and we have been through the process with many medical device and IVD companies that we guarantee you will pass your first ISO certification audit if you follow our plan.
•We fully customize ISO 13485 quality systems for our clients.
•Our ISO 13485 consulting and project management teams will work closely with you to ensure that your quality system is implemented on time and on budget.
•On-site ISO 13485, CE Marking, and Canadian Medical Devices Regulations training for your key employees is included in the cost of an Emergo Group quality system.
•All of our projects are based on a fixed price.
CE Mark Consultants and CE Marking for Medical Devices
Before you can sell a medical device or IVD within Europe, you must obtain CE Marking certification and place a CE Mark (CE Marking) on your product. The CE Marking for medical devices is not a quality mark nor is it intended for consumers. It is a legally binding statement by the manufacturer that their product has met all of the requirements of the Medical Devices Directive (MDD 93/42/EEC), In Vitro Diagnostic Device Directive (IVDD 98/79/EC) or the Active Implantable Medical Device Directive (AIMDD 90/385/EEC), where applicable. If a Notified Body is required, the Notified Body's four-digit number would appear below the CE Marking symbol.
CE Marking Checklist:
The Medical Devices Directives state that companies must do the following before they can place the CE Marking on a medical device or IVD:
•Compile a medical device CE Marking Technical File (or Design Dossier for Class III) with evidence of compliance to the Medical Devices Directive (or the IVD/AIMD Directives).
•Receive a medical device CE Mark certificate from a Notified Body if Class I with Measuring or Sterile function, Class IIa, IIb, or III, or if Annex II, List A; Annex II, List B, or self-testing IVD.
•Appoint a European Authorized Representative if you have no physical location in Europe.
•Register medical devices with the EU Competent Authorities, where applicable.
Only after these CE Marking requirements are satisfied are you allowed to place the CE Marking on your medical device.
Our CE Marking Services:
Emergo Group has assisted hundreds of companies with medical device CE Marking. Our services include:
•CE Marking Technical File or Design Dossier compilation and review.
•Verification of Essential Requirements.
•Product classification and identification of applicable standards for medical devices.
•Implementation and maintenance of ISO 13485 quality systems.
•Product labeling and packaging review.
•Risk assessment and management (ISO 14971).
•Development of Vigilance and Post Market Surveillance including Vigilance Standard Operating Procedures and Processes.
•Authorized Representative for Europe.
Our quality management systems can meet European CE Marking & other international requirements
Emergo Group can develop a compliant quality management system by applying ISO 13485:2012 to ensure you meet the quality system requirements for Europe. Each system is customized for the manufacturer and can not only ensure compliance to the European Directives for Medical Devices (CE Marking), but also to the Canadian Medical Devices Regulations, United States FDA QSR, Australian TGA requirements, and Japanese Pharmaceutical Affairs Law.
This place is like a Wal-Mart for your one stop shop for all your shopping needs.
Medical Device Logistics ConsultingEmergo Group can assist you with determining the best solutions for shipping your products. When exporting products many medical device companies start by shipping orders direct to distributors or customers. However, as the frequency of orders and order volumes increase it may become lucrative to consolidate orders in bulk shipments or to establish a suitable warehousing arrangement.
Warehousing & Transportation
In situations where companies are shipping direct to multiple distributors or customers, consolidation of these shipments may result in significantly lower shipping costs. And instead of requiring each distributor to keep a minimum inventory level, you as the supplier can decide to keep products warehoused in a centralized location to reduce total inventory levels in the supply chain while maintaining the option to ship next day to the distributors and customers. Results are cost savings in the supply chain, higher service levels to distributors and customers, and increased market share.
When importing products into Europe and warehousing these products in a centralized location, customs duties and value added tax (VAT) apply.
Customs Duties and Value Added Tax (VAT)
Postponement of customs duties can be arranged by warehousing your products in a customs bonded warehouse for an unlimited period of time. During this period no customs duties are due. Customs duties at import need to be paid when the goods are actually imported into the free circulation of the European Union.
Value Added Tax (VAT) is due upon import of products into the European Union and varies per EU country from 15-25%. This is a supply chain tax, and is refundable to businesses, usually by submitting a quarterly VAT return.
Finding and selecting warehousing & transportation partners
When looking for a third party logistics provider for your European warehousing and transportation needs, we can assist you with the following:
Step 1: Determine your medical device logistics needs
Depending on if you are starting up or optimizing your logistics operation(s), your needs can range from a distribution location to warehouse, pick, and ship your products to a full service value-added logistics facility where products can be assembled or customized to the specific needs of your customer base. The choice is yours! It is also possible to select a logistics provider as your fiscal representative.
Step 2: Identify potential EU logistics providers
Through our extensive logistics experience and existing network we are very familiar with the capabilities of logistics service providers specialized in medical devices. Based on your logistics needs we can identify the logistics providers that best fit your needs.
Step 3: Meet with potential logistics partners
Seeing is believing! We can set up on-site meetings for you with logistics providers that fit your needs and if required accompany you on these visits.
Well we don't know what it cost to hire Emergo Group, but I can say this, job well done SNDY for hiring such a great company to take this stock to the next level. If you had to sell some shares to make this happen, you spent our money well. I for one never questioned what was happening behind the doors at SNDY. I guess you can say the quite period is now over. I have said for the past 4 months when they have something of importance to tell us they will. I want to thank all the longs that has believed in SNDY over the past year and contributed to this board. I guess all those people spending 1.6 million dollars in SNDY preferred shares believed in them as well. We all know they was betting on the future of this company as well.
Take care my friends,
Mike
--------------------------------------------------------------------------------
Quote:
--------------------------------------------------------------------------------
ajsollii
Post # of 60019
When acquired, their shares would be absorbed and converted to the parent/new company's shares. No need to RS. The reason they gave was to make the company attractive to merger/acquisition. CE will do that nicely...as it did with the 95% of companies who exited via merger or acquisition after obtaining both CE and FDA approval. We know what's really going on. This is going to be a fun ride. $1? No. Not in the short term. But .25 isn't outside the realm of the possible. IMO...
--------------------------------------------------------------------------------
Quote:
--------------------------------------------------------------------------------
Looks like we have been warned over and over and over again that this stock will never go up because of all the diluted shares. Well according to the charts, if we compare price movement and volume the dilution is not hindering the stock price to run.
Lets go to bigcharts and see the facts for ourselves.
bigcharts.marketwatch.com/interchart/interchart.asp?symb=SNDY&insttype=Stock&time=20&freq=3
Once you open the link go to the left box click timeframe, then click chart range, then click 2 years.
Now lets look at volume and price movement. That is the telling story with the tradeable float. Slide your cursor on the bottom part of the chart and you will see for yourself the volume/date and price.
Date.............Price....Volume
Jan 27,2012 .0008 92,780,424
Feb 3, 2012 .001 138,243,856
Feb 10,2012 .003 148,966,600
Feb 17,212 .008 676,904,500
Total Volume 1,056,895,380 That is over 1 billion shares
traded in 3 weeks.
Float at this time was only 379,000,000
Date.............Price....Volume
March 9, 2012 .004 85,953,790
March 16,2012 .007 146,009,456
March 23,2012 .017 335,275,736
March 30,2012 .018 287,097,184
Total Volume 854,336,166 Over 3/4 million shares traded in
3 weeks and a 350% increase in price. Also remember we had big news that came out on March 23 that drove the price.
Float at this time was only 379,000,000.
Date...........Price....Volume
Feb 1,2013 .004 42,879,750
Feb 8,2013 .004 119,606,072
Feb 15,2013.006 103,673,360
Feb 22,2013.008 92,857,000
Total Volume 359,016,182, thats 58% less volume then the run we had from March 9th thru March 30th. Price increase of 100%.
Float at this time was 640,000,000.
A 41% increase in shares from the March 2012 run and yet the price moved just as easily.
Even the run up the July 18 went from .002 to .0038 on only 105,000,000 shares that day. Up over 80% and with a float of over 850,000,000 shares!!
These are FACTS that can't be dispelled no matter what anyone says. Yes the FACTS are they increased the O/S by 261 million shares during that time. But the FACTS also tells us those shares are not in the open market,(meaning when SNDY is selling these shares someone is buying them instead of them being just dumped into the open float of tradeable shares). If the float was that much bigger it would of taken at LEAST TWICE AS MUCH VOLUME TO MOVE THE STOCK PRICE UP ON THE RUN BACK IN FEBRUARY 2013.
I would agree with what many are saying about them diluting shares if they were being added to the tradeable float. The stock price would be very very hard to move up when you have a much larger float. But the FACTS shown in this chart with the price to volume ratio just do not support that the dilution will kill any run up in price. Sorry but it is simply the facts.
Yes SNDY has been selling shares but a lot of people on this board are buying. And this chart tells us that someone is buying them instad of them being dumped in the open market. Booper, Muff1, Blueski, Mgergo, Pennylanepam, Vert, Elcappy1, Frazier, Ichase01 and many others including myself have been buying millions of shares since February 2012. And the chart says exactly that.
Take care my friends,
Mike
--------------------------------------------------------------------------------
Quote:
--------------------------------------------------------------------------------
We are starting to see why big money...
has been investing in SNDY. The payoff is going to come when they get the CE mark approval. I have been adding every week for that past 3 months. My share totals no longer matters nor do the group of guys that are in this with me. I know what I own and have waited patiently for the payoff to come with a merger or partner/buyout with another medical company.
There is a reason these smart investors/venture capitalist are spending BIG money buying SNDY preferred shares. Remember this, investors that buy preferred shares are buying into the future of the company. They know what is coming and are taking a stake in the company. How much money are we talking about? Well here is the break down.
I have put together a list of the shares and the amount of money SNDY received by going thru their financial since 2nd Q 2011.
In the 2nd Q 2011 SNDY sold 4,000 preferred B stock options for $40,000 in cash. Bottom of Pg.19 of 4Q 2011 report.
In the 4th Q 2011 SNDY owed a contractor $400,000. This contractor took $400,000 worth of preferred B stock options and then gave SNDY $55,000 in cash for the purchase of additional shares. Pg.20 of 4Q 2011 report.
In the 1st Q 2012 a consultant received 26,000 shares of preferred B stock options for payment due of $260,000. Also they sold 10,900 share of preferred B stock options for $109,000 in cash. The entire board of SNDY also gave up their 150,000,000 shares of common stock to take preferred B stock options as well. Pg.15 of 1Q 2012 report.
In the 2nd Q 2012 the company sold 38,580 shares of preferred B stock options for 395,800 in cash. Also an officer and director took 27,015 shares of preferred B stock options for the conversion of $111,240 owed to him. Pg.15 of 2q 2012 report.
In the 3rd Q 2012 the company sold 26,150 shares of preferred B stock options for $261,500 in cash.Also the president recieved 450,000 shares of preferred B stock options for $450,000 owed to him for the signing of an employee contract and personal guarantees to the company. Pg.15 of 3q 2012 report.
There is obviously some major players with really deep pockets that have heavily invested into the future of SNDY. In cash advances to company alone they have received $861,300. Over 3/4 million dollars. Not to mention the contractors, consultants, and one officer receiving shares for money owed, in the amount of $771,240. Actually more cash money went into SNDY then people taking stock options as payments. That should say a lot. So we see that $1,632,540 in cash and stock option payments have been invested into the future of SNDY in a very short time. There is no one that is going to invest this kind of money into SNDY without knowing the payoff will be rewarding.
The thesis has been out for a few years and was one of the reasons while doing my DD that led me to buy so many shares of SNDY. One of the things that caught my attention a year ago in the thesis was at the end of page 52 and the first part of page 53. Here they are talking about venture capital investors buying preferred stock. And that is exactly what I saw with all the money going into SNDY with these investors buying preferred stock options. Also take a look at the last 2 paragraphs on page 83 and the first part of page 84. That is what SNDY did over the past 14 months, got cash flow positive and and reduced almost all debt.
I've been saying this company is in a quiet period and when it is time to release news they will. I'm glad they are not throwing out fluff PR's. It is giving me plenty of time to continue to buy more shares. I will stick by what I have said for the past 15 months. My money is invested into the future of SNDY and I believe my pay off will be well rewarding.
Take care my friends,
Mike
THIS SHOULD CLEAR ANY DOUBTS ABOUT A R/S...
If we want to use the history of SNDY past R/S, then you have to use all the history of SNDY past R/S. ALL THEIR PAST R/S DID EFFECT the preferred B shares. So if we are judging SNDY on their past actions, then we have to do so for the future as well.
Beside let’s cut to the real facts of a R/S. Even if they did a R/S say of 1 for 5000 do you realize how much smaller the float would be. This stock is so thin now can you imagine how thin it would be with a 1 for 5000 R/S. So with a float now of 660 million that would drop the float to 132,000 shares. Heck my entire group owns more then that.
So let’s do some math:
I've got 60,000,000 shares X .0078 = $468,000
After a 1 for 5,000 R/S I would then have 12,000 shares X $39.00 = $468,000. So I still have the same exact amount of money.
Now we would have a stock price at $39.00 with a float of only 132,000, and say at the same time they announce a partnership/merger along with news of them receiving the CE mark. Remember they have to have a European partner to obtain the CE mark. If you think the trading is tight not just imagine with the float dropping from 660 million, down to only 132,000 shares in the float. Talk about fuel for the fire. Also by having such a high share price of $39.00 it would remove the volatility even if they don't get the CE mark. I as an investor would welcome it. But I don't see it happening.
NOW THE REAL REASON WHY A R/S WANT HAPPEN.
If they do a 1 for 5000 R/S without effecting the preferred B shares like some keep saying. Then our COMMON SHARES at a R/S price of $39.00 would be worth more than the insiders preferred B stock options who only got $4.11 per share for their preferred B stock options when they gave up their 150 million common shares Feb 2012. The $4.11 per share figure was in the financial report.
So who in their right mind believes the insiders would actually allow our common shares to be worth more than their preferred B stock option share? FOLKS THAT IS NOT GOING TO HAPPEN!! I DON'T CARE HOW HARD ANYONE TRIES TO SPIN IT. SO IF THAT IS NOT GOING TO HAPPEN, THEN YOU HAVE TO BELIEVE A R/S IS NOT GOING TO HAPPEN. JUST SAYIN'
Take care my friends,
Mike
"Even though the auditors who are completing the CE Certification process have a 100% success record in attaining the CE Mark for clients, potential business partners may still want to wait until the Certification is successfully completed before they partner or merge with SNDY. However, if a potential partner is just as interested in bolstering up U.S. sales while waiting for European and Canadian sales to kick in, it could happen sooner."
--------------------------------------------------------------------------------
Quote:
--------------------------------------------------------------------------------
A/S 851M shares with just about 100M before being maxed. Highly unlikely the company increases A/S before a major milestone (CE Mark).
SNDY Current MC $1.702M. Obviously way undervalued even with the current S/S. SNDY BV $2.15M
I didn't particular like 190M new shares to hit the market (it reduces expected ROI) but it was as transparent as it comes. It hasn't been hard (at all) to track where the dilution is coming from, Preferred shares (that have been issued to Boost) are being converted to common shares. It's funny how nobody is talking about how all these shares have been absorbed at or above the 52 week low ahead of the CE Mark. $0.002 continues to be strong support.
The company has been able to continue carrying very little debt (Current Liabilities ~$173K). Solos has been able to keep its balance sheet very healthy despite how long the ISO process has taken. Costs associated with the CE Mark are finished, the company has the opportunity to reach quarterly profitability by increasing revenue a few hundred K.
Also important
Authorized Preferred Shares: 20M shares with only 650K outstanding.
No reason to authorize so many Preferred Shares if you don't expect to use them to generate capital.
A/S will likely increase at some point but the question is by how much. The CE Mark is a huge deal for a small medical device company looking to form a partnership or exit via M&A. CE Mark combined with international distribution would lead to a significantly higher PPS.
GLTA
mgrego
----
"With this complete service package, TUV SUD can assist medical companies in accessing markets nationally, in Europe, and globally."
The company that SOLOS has contracted with to enable them to attain the CE Certification has a 100% success record at accomplishing the CE Certification for companies it has worked with. The CE Mark is pretty much a given, but the street won't believe it until it is official. In the meantime, the most important event we are waiting for is the business partnerships the President of SOLOS alluded to in his letter to shareholders.
---
I don't recall "all" the longs here, or any for that matter, saying that SNDY is trading "great" now. However IMO it is best for the long term, to get all the peeps out of the stock that wanted to be overnight millionaires and replace them with actual INVESTORS in the company, not short term TRADERS or flippers of the stock. Being a shareholder of the company is not the same as being an investor in the company. Too many insecure faux long shareholders had their finger constantly hovering over the sell button, flinching and agonizing with daily ups and downs, instead of holding on to their stock and waiting for the positive, successful SNDY business story that has been gradually emerging and continues to unfold.
-
Penny stocks can eventually uplist to bigger boards like NASDAQ and AMEX. It takes time and patience. It does not happen overnight as the process from moving from the Pink Sheets, to the OTCBB and then to the AMEX or NASDAQ usually takes at least a couple of years. Over the last 15 years, I have owned penny stocks that eventually moved up and went from trading at .04 on the OTCBB, to trading at $4.00 on the AMEX . Unfortunately, I sold all but one of them while they were still pennies! They don't always make it once they move up to the NASDAQ or AMEX either. Nothing is easy .
---
The company is debt free and profitable. There is no more reason to dilute. They had to increase the A/S regardless, because the O/S had reached 495 mil, which left only 5 mil left in the A/S. That is a dangerous position for a company to be in. Anyone who thinks it would be better if the company did not raise the A/S, and sat with 495 out of 500 mil in the A/S are mistaken. Now the company has shares available for merger/acquisition/partnership. If they had not increased the A/S, they would be not be in a position to enter into those partnerships. They also had to protect themselves as they would have been vulnerable to hostile takeover from another company or person buying up a majority of shares.
--
Listen Jack, if you "know" so much about what a company automatically does after they increase the A/S, then you were foolish not to sell when the O/S reached 495 million out of 500 mil. Everyone had plenty of time to do so before the A/S increase. Once the O/S maxes out like that, a company would be negligent NOT to increase the A/S to protect itself and its shareholders. If you didn't know that, which is something that is basic knowledge when trading pinkies, then you certainly don't "know" what the company plans on doing next.
---
Few events strike as much fear in the hearts of start-up investors as dilution. Many go through great lengths to include anti-dilution clauses that protect the specific percent share of a company that they signed up for. If they buy or earn 10% of a company then they want to keep 10% of the company, often with little thought to the underlying value of the company. Dilution, however, isn’t necessarily a bad thing. In fact, dilution can be a great sign that your company is growing and doing the right things.
Dilution is a natural adjustment in ownership that occurs when the company distributes more shares to those who deserve it. So, if I own 50 out of 100 shares I own 50% of the company. If it’s a start-up company my 50% is probably worth nothing. However, if the company sells half the company for $1,000,000 and issues another 100 shares my ownership dilutes to 25% instead of 50%. However, the underlying value of my ownership went from being worthless to being worth $250,000. In this case, dilution is a good thing. I never would have built value in the company unless I was willing to be diluted.
Our fear of dilution will often have a negative impact on our ability to succeed. It will prevent us from bringing on valuable partners or employees that might deserve equity in our company. Our inability to realize that a small percent of something is infinitely better than a large percent of nothing holds us back.
The reason people fear dilution is because we don’t want to be taken advantage of by other participants in the company. If I invest in a company and receive 10% of 100 shares (10 shares) what’s to prevent the owners from simply granting more shares to themselves and diluting my shares with no gain in value? In this case other people will benefit at my expense. However, the reverse is also true. If the company has to issue me more stock whenever they issue stock to someone else I am essentially getting more stock for doing nothing. So, I am benefiting at the expense of others. Both scenarios are problematic. However, most of us would rather have the problem of getting more than we deserve.
In an ideal world every participant in the company would get exactly what they deserve—no more and no less. If we are all getting exactly what we deserve then there is no reason to worry about dilution. You can always rest assured that no matter what your share, it is always fair relative to others. The only way to achieve this, however, is through the use of a dynamic equity split program. Dynamic splits are not widely used today because they are not widely understood. Most companies use a fixed or static-split which is very difficult to keep fair. We try to compensate by using vesting programs, options programs and numerous protection clauses like anti-dilution. Equity negotiations are among the most painful and destructive events at a start-up. They pit people against each other who should be working together. It’s every man for himself.
However, in a dynamic equity model everyone is guaranteed to get what they deserve. In a dynamic model a relative value is put on the various contributions people make to the start-up. Contributions can include time, money, ideas, relationships, equipment, faculties and other necessities that help a business grow. You calculate ownership by dividing what you contributed by the total of all the contributions made by everyone on the team. Therefore, your percent ownership is always exactly what you should have. Dynamic models change during the early days of a start-up so dilution is a natural part of the process.
Dilution, under the right circumstances, is a positive sign that everyone in a start-up company is being treated fairly by everyone else. Under the wrong circumstances dilution is a sign of greed, mistrust and ego.
SNDY PR’s 2008 - 2013
06/06/2008 SNDY Completes Stock Split and Changes Symbol to SNDY
10/02/2008 SNDY and Its Products Appear in Worldwide Global Endoscopic Systems Market Report
10/08/2008 SNDY Posts First Six Months Financials of 2008 on Pinksheets.com
10/14/2008 SNDY in Final Stages to Upgrade Pink Sheet Status from Limited to Current Information
10/20/2008 SNDY Reports an 18% Increase in Sales during 3rd Quarter of 2008
10/23/2008 SNDY Applauds American College of Surgeons Review of Advanced Breast Cancer Detection at 94th Annual Clinical C
10/30/2008 SNDY Mammo View(TM) System Now Used in Women's Hospital of Baton Rouge, LA
11/06/2008 SNDY Receives Purchase Order from Connecticut Hospital
11/14/2008 SNDY Mammo View(TM) System Introduced in Puerto Rico to Promote Breast Health
11/20/2008 SNDY Receives Purchase Order from Clarian Health Partners for Mammo View(TM) System
12/10/2008 SNDY Increases Sales Revenue for October 2008 by Over 10% as Compared to Last Year
01/06/2009 SNDY Receives Purchase Order from Cleveland Clinic
02/11/2009 SNDY Posts First Nine Months Financials for 2008 on Pinksheets.com
02/19/2009 SNDY MammoView(TM) Featured in December Issue of Surgical Products Magazine
02/24/2009 SNDY Breast Endoscopy System Featured in January Issue of Outpatient Surgery Magazine
02/26/2009 SNDY Receives Purchase Order from Major Connecticut Hospital for the MammoView(TM)
03/03/2009 SNDY Successfully Completes FDA Inspection
03/20/2009 SNDY Sells Ovascope and Mastascope Product Line to Lifeline Biotechnologies
03/24/2009 SNDY Receives Purchase Order from Leading San Diego Healthcare Provider
04/02/2009 SNDY Develops Specialized Endocoupler for the MammoView(TM)
09/10/2009 SNDY Receives Purchase Order from One of the Major Healthcare Systems in Missouri
09/17/2009 SNDY Receives Purchase Order from the National Cancer Institute
09/21/2009 SNDY MammoView(TM) Product Line Receives New Purchase Orders Primarily from Prestigious Teaching Hospitals
09/23/2009 SNDY Receives Purchase Order from a University Teaching Hospital in Arkansas
09/29/2009 SNDY Receives Purchase Orders from Leading New York City Healthcare Center
10/06/2009 Small Company Offering and Sale of Securities Without Registration (D)
10/07/2009 SNDY MammoView(TM) Product Line to be demonstrated at the 95th Annual American College of Surgeons Clinical C
10/14/2009 SNDY FDA Approved MammoView(TM) Product Line to Obtain CE Mark
10/16/2009 SNDY Receives Multiple Purchase Orders for its MammoView(TM) Product Line
10/23/2009 SNDY Receives Additional Purchase Orders from National Cancer Institute and National Institute of Health for it
10/27/2009 SNDY Receives Purchase Orders from BJC HealthCare for its MammoView(TM) Product Line
10/29/2009 SNDY Receives Purchase Orders from University of California, San Diego Medical Center for its MammoView(TM) Pro
11/03/2009 SNDY Receives Purchase Orders from Catholic Health Initiatives for its MammoView(TM) Product Line
11/05/2009 SNDY Has Retained Services of Experienced Medical Marketing Firm for a 2010 Campaign
11/11/2009 SNDY Breast Endoscopy System Featured in November Issue of Healthcare Purchasing News Magazine
12/09/2009 SNDY Reports Sales Increase for October 2009 and November 2009 as Compared to Same Two Months in 2008
12/18/2009 SNDY Makes Significant Design Improvement to Its MammoView(TM) Ductoscope
12/23/2009 SNDY Outlines Marketing Strategy for 2010 Campaign
12/30/2009 SNDY Set to Increase Business through Sales and Product Development in 2010
01/15/2010 SNDY Breast Endoscopy System Featured in February Issue of General Surgery News
01/22/2010 SNDY Reports a 9% Increase in Sales for the 4th Quarter 2009 as Compared to 4th Quarter 2008
02/05/2010 SNDY Retains Expert Resource to Meet Requirements for ISO 13485 Quality Management System Initiative
02/16/2010 SNDY Set To Develop New Polymer Dilator For MammoView(TM) System
03/18/2010 SNDY Granted U.S. Trademark for MammoView(R)
04/13/2010 SNDY Successfully Completes Phase One Requirements for ISO 13485 Quality Management System Initiative
04/16/2010 SNDY Posts Financial Results for Year Ending 2009
05/21/2010 Appoints Experienced CFO To Financial Leadership Amidst Growth
05/26/2010 SND Increases Revenues by 10 Percent for First Quarter 2010 as Compared to First Quarter 2009
06/15/2010 Develops Relay Lense Adapter System For MammoView® Product Line
06/24/2010 Breast Endoscopy System Featured in July/August Issue of The Breast Journal
07/13/2010 SNDY Reports a 30% Increase in Sales for June 2010 as Compared to June 2009
08/26/2010 SNDY Reports Revenues for First Six Months of 2010
09/21/2010 SNDY to Hold Annual Shareholder Meeting September 28, 2010
09/30/2010 SNDY Announces Results of 2010 Annual Shareholder Meeting
10/27/2010 SNDY Revenue Grows 34.8% for Third Quarter 2010
11/19/2010 SNDY Announces Recapitalization Plan for 2011
01/06/2011 SNDY Trends toward Strong Continued Growth in 2011
01/27/2011 SNDY Reports $90,005 in Sales Revenue for Fourth Quarter 2010
02/10/2011 SNDY Reports $34,291 in Sales Revenue for January 2011
02/23/2011 SNDY To Introduce New Urology Instrument Line
03/24/2011 SNDY Strengthens Current Line of Laparoscopic Instruments
04/19/2011 SNDY Decreases Net Loss by Over $1 Million
06/14/2011 SNDY Receives Multiple Purchase Orders From Major Cancer Institutes and Research Centers
06/22/2011 Statement of Beneficial Ownership (SC 13D)
06/30/2011 SNDY Enters Multi-Billion Dollar Veterinary Market with Launch of Revamped Endoscopic Veterinary Product Line
06/23/2011 SNDY To Launch New Corporate Website
07/07/2011 Statement of Beneficial Ownership (SC 13D)
07/20/2011 SNDY MammoView® System Proves Crucial to Early Breast Cancer Detection
08/23/2011 SNDY to Reduce Debt by Over $620,000
09/15/2011 SNDY Reports 32% Increase in Breast Endoscopy Sales
09/23/2011 SNDY to Market its MammoView® Breast Endoscopy Components to US Hospitals
10/06/2011 SNDY to Support National Breast Cancer Foundation With Sales of Its MammoView® Breast Endoscopy Components to US .
10/21/2011 SNDY Finishes the 3rd Quarter Strong
11/03/2011 SNDY Goes Google
11/17/2011 SNDY Poised for Tremendous Growth in Multi-Billion Dollar Endoscopic Market
11/22/2011 SNDY Finishes the 3rd Quarter With a Net Profit
12/22/2011 SNDY Reports Significant Sales From Its MammoView® Instrument Line
12/29/2011 SNDY is Primed for Growth in 2012
02/14/2012 SNDY Announces Retirement of 150 Million Common Shares
02/14/2012 Panache Beverages (WDKA) Presence Solid in the State of Florida
03/02/2012 SNDY Successfully Completes Level I FDA Inspection
03/16/2012 SNDY to Launch New SteriTAP™ Endoscopic Instrument Line
03/22/2012 SNDY and Opko Health Benefit From Booming Medical Equipment and Supplies Industry
03/30/2012 SNDY Reduces Net Loss by More Than $688,000
04/25/2012 SNDY Reduces Liabilities by More than $570,000
05/04/2012 SNDY to Finalize ISO 13485 Certification and CE Mark Initiative with Expert Resource for Endoscopic Instruments
04/30/2012 SNDY Sales Increase by 16% for First Quarter 2012
05/16/2012 SNDY Posts Net Profit for First Quarter 2012
05/23/2012 SNDY Releases ISO 13485 Certification and CE Mark Schedule With Work to Begin May 29
06/13/2012 SNDY Reduces Inventory Cost and Improves Gross Profit Margin for Second Quarter 2012
06/19/2012 SNDY to Expand Internationally its MammoView® Breast Endoscopy Product Line
07/13/2012 SNDY Begins Marketing the New SteriTAP(TM) Endoscopic Instrument Line
07/25/2012 SNDY Bariatric Instruments Are Now Available
08/16/2012 SNDY Posts Total Assets of $2,426,883 for Period Ended June 30, 2012
08/21/2012 SNDY Retains TUV SUD America to Complete ISO 13485 Certification and Audit
09/27/2012 SNDY Celebrates 25 Years of Quality Innovative HealthCare for the Multi-Billion Dollar Endoscopic Market
10/11/2012 SNDY Reports Significant Progress on ISO 13485 Certification and Audit
10/24/2012 SNDY Manufacturer to Conduct New Testing to Increase Sterilization Life for its MammoView® Breast Endoscopy
11/08/2012 SNDY Sales Increase by More than 35% for the Month of October
11/14/2012 Quarterly Report
11/15/2012 SNDY Reports Book Value of $2,393,522 for Period Ended September 30, 2012
12/14/2012 SNDY Sales Increases by More than 53% for the Month of November, 2012
12/14/2012 Attorney Letter with Respect to Current Information
12/14/2012 Quarterly Report
01/04/2013 SNDY Management Announces Goals for 2013
01/16/2013 SNDY Finishes 2012 Strong
01/24/2013 SNDY and TUV SUD America Schedule Stage 1 ISO 13485 Audit for February 26, 2013
03/04/2013 Officer/Director Disclosure
10:06 a.m. June 12, 2013
Solos Endoscopy and TUV SUD America Schedule Stage 2 ISO 13485 Audit for August 16, 2013
1:01 p.m. July 18, 2013
Solos Endoscopy's MammoView(R) System Offers Women Early Breast Cancer Detection
9:06 a.m. Aug. 2, 2013
Solos Endoscopy Retains Emergo Group to be the Authorized Representative for the Importation of Solos Instruments into Europe
****************************************************************
SNDY SEXY CHART
SNDY L2 screenshot
A presidents letter to shareholders about CE mark is what I believe would be released from the company. A milestone like that is a major step to the next level.
Only FACT is expected CE mark approval in 11 days.
CE mark is a major achievement, most pinks never get that far.
European and Canadian markets will be open for distribution.
BILLION DOLLAR MARKET
$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$
YOU ALL HAVE BEEN WARNED!
SNDY SEXY CHART (GOBBLEDY GOOK)
WHATS LEFT IN CE MARK PROCESS....
AI
